{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:04:48Z","timestamp":1789473888649,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijid.2022.06.059","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T17:13:47Z","timestamp":1657127627000},"page":"599-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19"],"prefix":"10.1016","volume":"122","author":[{"given":"Carsten Schade","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.06.059_bib0001","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2022.06.059_bib0002","series-title":"Paxlovid Summary of Product Information","year":"2022"},{"key":"10.1016\/j.ijid.2022.06.059_bib0003","series-title":"Article 5(3) procedure","year":"2021"},{"key":"10.1016\/j.ijid.2022.06.059_bib0004","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/eurheartj\/ehab697","article-title":"ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up","volume":"43","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijid.2022.06.059_bib0005","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.06.059_bib0006","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.06.059_bib0007","doi-asserted-by":"crossref","first-page":"e695","DOI":"10.1093\/cid\/ciaa1419","article-title":"Risk factors for coronavirus disease 2019 (COVID-19)-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system","volume":"72","author":"Ko","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.06.059_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral Nirmatrelvir\/Ritonavir (Paxlovid) and comedications","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2022.06.059_bib0009","unstructured":"Medstat.www.medstat.dk, 2021 (accessed 05 April 2022)"},{"key":"10.1016\/j.ijid.2022.06.059_bib0010","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2020.08.041","article-title":"Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19","volume":"76","author":"Nadkarni","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijid.2022.06.059_bib0011","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/jac\/dkaa253","article-title":"Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect","volume":"75","author":"Stader","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.06.059_bib0012","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, 2021","volume":"23","author":"Steffel","year":"2021","journal-title":"EP Europace"},{"key":"10.1016\/j.ijid.2022.06.059_bib0013","doi-asserted-by":"crossref","unstructured":"Statistics Denmark.www.dst.dk, 2022 (accessed 05 April 2022)","DOI":"10.1787\/f7ae56ab-en"},{"key":"10.1016\/j.ijid.2022.06.059_bib0014","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1038\/s41598-021-88130-w","article-title":"A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19","volume":"11","author":"Thakur","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2022.06.059_bib0015","unstructured":"University of Liverpool COVID-19 drug interactions database.www.covid19-druginteractions.org, 2022 (accessed 5 April 2022)"},{"key":"10.1016\/j.ijid.2022.06.059_bib0016","doi-asserted-by":"crossref","unstructured":"Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir\/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA.2 wave: an observational study. medRxiv 20 May 2022, https:\/\/www.medrxiv.org\/content\/10.1101\/2022.05.19.22275291v1 (accessed 7 July 2022).","DOI":"10.1101\/2022.05.19.22275291"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222003915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222003915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T10:46:19Z","timestamp":1715424379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222003915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":16,"alternative-id":["S1201971222003915"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.06.059","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.06.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}